Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

The two-dose vaccine has been shown to have benefits beyond just developing shingles, although that alone should be impetus ...

During the 2019 pandemic sweeping through hospitals, an insidious companion emerged in bloodstream infections, where bacteria ...

Five members of staff and one dedicated volunteer from Buckinghamshire Healthcare NHS Trust were honoured at a Royal Garden ...

Saheed Ahmed, a final-year veterinary student at the UI, has been named the World's Best Veterinary Student by the WVA.

New research analysing an online survey of 1,633 respondents found 15% recent use of doxycycline post- and pre-exposure prophylaxis (doxyPEP/PrEP ...